INDIA – Berry Global to begin product production at its new manufacturing facility and healthcare center of excellence in Bangalore, India as early as April 2023.
Leveraging the company’s innovative research and development (R&D) solutions, this new Greenfield expansion project will: Improve regional and global access to advanced healthcare solutions.
It will also provide customers with the necessary volume to support the forecasted growth for Asia’s domestic healthcare market.
In addition, the project is expected to boost India’s domestic economy by employing more than 500 new team members over the next eight years in Bangalore, commonly referred to as India’s Silicon Valley
Tom Salmon, Berry Global’s Chairman and CEO said: “Healthcare companies have limited access to regional expertise and global capabilities needed to provide patient populations in Asia with modern healthcare solutions at scale.
“Our new facility and global healthcare center of excellence in Bangalore will support Asia’s growing demand for healthcare products, create new jobs, and, most importantly, benefit the lives of patient populations who have historically gone untreated and under-diagnosed.”
The new Bangalore plant will improve global patient access to products for the Inhalation, Nasal, Ophthalmic, Dispensing, and Self-injection industries.
According to the company, the new Berry Global Healthcare R&D Center of Excellence will support the development of innovative solutions for existing and new applications to improve medicine administration and functionality, while helping customers’ meet ambitious sustainability goals.
The R&D center will launch up to seven new products and projects in 2023, ranging from Dry Powder Inhalers (DPI) to plastics caps and closures.
Among these products will be Berry’s Pneumohaler, a lightweight, breath-actuated, multidose inhaler dose counter for the control and treatment of Asthma and Chronic Obstructive Pulmonary Disease.
Located near some of the largest, generic pharmaceutical companies, the Bangalore site’s ability to cater pharmaceutical packaging to U.S. regulatory requirements will enable the local manufacture of healthcare products, at a global scale.
The site will use ISO class clean rooms, as well as leverage Berry’s experience submitting Active Drug Master Files (DMFs) to regulatory agencies and providing active DMF and filling for regulated markets.
Jean-Marc Galvez, President of Consumer Packaging International said: “Improved drug affordability and greater access to modern healthcare solutions are more important than ever in India, one of the most populated countries in the world.
“Our new facility and R&D center will benefit the domestic economy by creating new jobs and the regional economy overall by improving healthcare access and providing locally manufactured products.”
Berry’s new Bangalore site will source the equivalent of around 90% of the facility’s electricity from solar and wind power.
The site has also achieved the International Sustainability and Carbon Certificate (ISCC) Plus designation.
ISCC Plus certified facilities support customer demand for more sustainable packaging by ensuring materials meet the ISCC’s standards for recycled, renewable, and recycled-renewable materials.
This provides traceability along the supply chain and verifies certified companies meet high environmental and social standards.
For all the latest packaging and printing industry news from Africa and the World, subscribe to our NEWSLETTER, follow us on Twitter and LinkedIn, like us on Facebook, and subscribe to our YouTube channel.
